ICER Draft Evidence Report on Lykos’ MDMA-Assisted Psychotherapy Deems Clinical Evidence “Insufficient” Post published:March 27, 2024 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #159: Patient Access to MDMA-Assisted Therapy; Notes from SXSW; Whole Mushroom vs. Synthetic Psilocybin Post published:March 21, 2024 Post category:Psychedelic Bulletin/Pα+
Notes from the International Society for Research on Psychedelics’ 2024 Conference in New Orleans (Guest Contribution) Post published:March 20, 2024 Post category:News/Opinions
Fluence’s Elizabeth Nielson on Professional Education for the Psychedelics Field Post published:March 19, 2024 Post category:Interviews/Pα+
Natural Medicine Advisory Bulletin 9: Feb/Mar 2024 Post published:March 15, 2024 Post category:Colorado Natural Medicine Advisory Bulletin
Gilgamesh Scoops $14m from NIDA to Develop Safer Ibogaine Analog for Opioid Use Disorder Post published:March 14, 2024 Post category:Analysis/News/Pα+
Cybin Scores Breakthrough Therapy Designation for Deuterated Psilocybin Analog in MDD, Shares 4-Month Data Post published:March 13, 2024 Post category:Analysis/News/Pα+
Bay Staters for Natural Medicine Co-Founder, James Davis, on Grassroots Psychedelic Policy Reform, a Community-based Facilitator Network, and the Corporatisation of Psychedelics Post published:March 8, 2024 Post category:Interviews
FDA Hands MindMed’s LSD Candidate Breakthrough Therapy Designation in Generalised Anxiety Disorder; Company Provides 12-Week Data and Fleshes Out Phase 3 Program Plans Post published:March 7, 2024 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #158: Fluence Brings Psychedelic Therapy Training to Ukraine; MindBio’s Microdosing Readout; Biomind’s 5-MeO-DMT Study; and more… Post published:March 6, 2024 Post category:Psychedelic Bulletin/Pα+